Literature DB >> 22086308

Comment on: Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis.

B Jönsson, O Ström, J A Eisman, A Papaioannou, E S Siris, A Tosteson, J A Kanis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22086308      PMCID： PMC5096933          DOI： 10.1007/s00198-011-1830-8

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  1 in total

1.  Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.

Authors:  B Jönsson; O Ström; J A Eisman; A Papaioannou; E S Siris; A Tosteson; J A Kanis
Journal:  Osteoporos Int       Date:  2010-10-09       Impact factor: 4.507
  1 in total
  4 in total

Review 1.  Denosumab: a review of its use in the treatment of postmenopausal osteoporosis.

Authors:  Marit D Moen; Susan J Keam
Journal:  Drugs Aging       Date:  2011-01-01       Impact factor: 3.923

2.  Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta.

Authors:  R Bargman; R Posham; A L Boskey; E DiCarlo; C Raggio; N Pleshko
Journal:  Osteoporos Int       Date:  2011-09-08       Impact factor: 4.507

Review 3.  A brief history of FRAX.

Authors:  John A Kanis; Helena Johansson; Nicholas C Harvey; Eugene V McCloskey
Journal:  Arch Osteoporos       Date:  2018-10-31       Impact factor: 2.617

4.  What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia.

Authors:  Jonathan Karnon; Ainul Shakirah Shafie; Nneka Orji; Sofoora Kawsar Usman
Journal:  Cost Eff Resour Alloc       Date:  2016-10-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.